VIDEO: Physicians must wait for STAMINA data to ‘really play out’ for posttransplant myeloma treatment

SAN DIEGO — Saad Z. Usmani, MD, FACP, director of plasma cell disorders and director of clinical research in the department of hematologic malignancies at Levine Cancer Institute at Carolinas HealthCare System, spoke with HemOnc Today at the ASH Annual Meeting and Exposition about the impact of the results from the STAMINA trial.

The randomized, phase 3 STAMINA trial — the largest randomized comparison of posttransplant approaches in myeloma in the United States — included 758 transplant-eligible patients aged 70 years or younger with symptomatic myeloma.

All patients underwent autologous hematopoietic cell transplant with melphalan 200 mg/m².

Patients then underwent one of three regimens: lenalidomide (Revlimid, Celgene) maintenance alone; RVD consolidation with bortezomib (Velcade, Takeda), lenalidomide and dexamethasone, followed by lenalidomide maintenance; or second autologous hematopoietic stem cell transplant followed by lenalidomide maintenance.

At 38 months, researchers reported no statistically significant differences in PFS or OS between the three treatment groups.

“Most transplant trials when comparing one modality to the other, the curves don’t start separating until about the 5- or 6-year mark,” said Usmani, a HemOnc Today Editorial Board member. “So, even though the data show no differences, we still have to wait a little while and see how the data really play out.” – by Kristie L. Kahl

Reference:

Stadtmauer EA, et al. Abstract LBA-1. Presented at: ASH Annual Meeting and Exposition; Dec. 3-6, 2016; San Diego.

Disclosure: Usmani reports no relevant financial disclosures.